You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Image-guided planning system for skull correction in children with craniosynostos

    SBC: KITWARE INC            Topic: NICHD

    DESCRIPTION (provided by applicant): Craniosynostosis is the premature fusion of cranial sutures and occurs in approximately one in 2000 live births. It results in cranial malformation that can lead to elevated intra-cranial pressure, brain growth impairment, and developmental deficiency. The most common treatment option for craniosynostosis is surgery. Currently, surgical treatment planning of cr ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a Nrf2 activator for the treatment of COPD

    SBC: CUREVEDA, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity worldwide. In the US alone, the disease afflicts ~13 million people and is the third-leading cause of death. Cigarette smoking isthe primary risk factor for COPD, initiating a persistent and progressive inflammatory immune response. Respiratory infections and pollutants can ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Evaluation of VBP15 a dissociative steroidal analogue on pain and inflammation

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NIMHD

    DESCRIPTION (provided by applicant): The treatment of pain in Sickle Cell Disease (SCD) is challenging for both patients and providers and is associated with significant disparities in healt care delivery. While the role of ongoing inflammation during vasooclusive crisis and pain is recognized, effective therapeutic interventions are lacking. Glucocorticoids, with their anti-inflammatory propertie ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Recombinant Botulinum Neurotoxin for Treatment of Spastic Disorders

    SBC: Cytodel, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Botulinum neurotoxin (BoNT) is the active ingredient in pharmaceutical products like Botox(R) (Allergan), which FDA has approved for therapeutic and aesthetic indications. Because of its inherent toxicity,the dose of BoNT required to treat spasticity disorders in large muscle groups is uncomfortably close to the toxic dose range. ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government